| Identification | Back Directory | [Name]
IMD-0560 | [CAS]
439144-66-8 | [Synonyms]
IMD-0560
Benzamide, N-[2,5-bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxy-
IMD-0560,inhibit,I kappa B kinase,IMD0560,Inhibitor,IκB kinase,IKK,IMD 0560 | [Molecular Formula]
C15H8BrF6NO2 | [MDL Number]
MFCD31630827 | [MOL File]
439144-66-8.mol | [Molecular Weight]
428.12 |
| Hazard Information | Back Directory | [Uses]
IMD-0560 is a novel IκB kinase β inhibitor. | [in vivo]
The tumor size is reduced in the IMD-0560-treated groups in a dose-dependent manner, and no tumor is detected in some mice treated with 5 mg/kg IMD-0560. Zygoma destruction is significantly suppressed in the IMD-0560-treated groups compare to the control groups. Although the tumor size in the 5 mg/kg IMD-0560-treated group is smaller than that of the 3 mg/kg IMD-0560-treated group, the inhibitory effect of each treatment on zygoma destruction is similar[1]. | [IC 50]
IKKβ | [References]
[1] Tada Y, et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma. Oncotarget. 2014 Dec 15;5(23):12317-30. DOI:10.18632/oncotarget.2640 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|